199 related articles for article (PubMed ID: 37341139)
1. Establishment and validation of a risk prediction model incorporating concentrations of linezolid and its metabolite PNU142300 for linezolid-induced thrombocytopenia.
Xu J; Lu J; Yuan Y; Duan L; Shi L; Chen F; Cao Y; Xu G; Feng Z; Li L; Xue H; Sun J; Zhou Q; Zhuang Z; Tang L
J Antimicrob Chemother; 2023 Aug; 78(8):1974-1981. PubMed ID: 37341139
[TBL] [Abstract][Full Text] [Related]
2. Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients.
Kawasuji H; Tsuji Y; Ogami C; Kimoto K; Ueno A; Miyajima Y; Kawago K; Sakamaki I; Yamamoto Y
BMC Pharmacol Toxicol; 2021 Mar; 22(1):13. PubMed ID: 33663616
[TBL] [Abstract][Full Text] [Related]
3. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients.
Matsumoto K; Shigemi A; Takeshita A; Watanabe E; Yokoyama Y; Ikawa K; Morikawa N; Takeda Y
Int J Antimicrob Agents; 2014 Sep; 44(3):242-7. PubMed ID: 25108880
[TBL] [Abstract][Full Text] [Related]
4. Risk factor analysis for linezolid-associated thrombocytopenia in critically ill patients.
Cazavet J; Bounes FV; Ruiz S; Seguin T; Crognier L; Rouget A; Fourcade O; Minville V; Conil JM; Georges B
Eur J Clin Microbiol Infect Dis; 2020 Mar; 39(3):527-538. PubMed ID: 31853741
[TBL] [Abstract][Full Text] [Related]
5. Contribution of human organic anion transporter 3-mediated transport of a major linezolid metabolite, PNU-142586, in linezolid-induced thrombocytopenia.
Wang D; Ikemura K; Hasegawa T; Yamane F; Okuda M
Biomed Pharmacother; 2024 Jun; 175():116801. PubMed ID: 38781867
[TBL] [Abstract][Full Text] [Related]
6. Classification Tree Analysis Based On Machine Learning for Predicting Linezolid-Induced Thrombocytopenia.
Takahashi S; Tsuji Y; Kasai H; Ogami C; Kawasuji H; Yamamoto Y; To H
J Pharm Sci; 2021 May; 110(5):2295-2300. PubMed ID: 33609520
[TBL] [Abstract][Full Text] [Related]
7. Linezolid-Associated Thrombocytopenia in Children With Renal Impairment.
Jones SJ; Nichols KR; DeYoung HL; Cox EG; Knoderer CA
J Pediatric Infect Dis Soc; 2015 Sep; 4(3):272-5. PubMed ID: 26407433
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for linezolid-induced thrombocytopenia in patients without haemato-oncologic diseases.
Choi GW; Lee JY; Chang MJ; Kim YK; Cho Y; Yu YM; Lee E
Basic Clin Pharmacol Toxicol; 2019 Feb; 124(2):228-234. PubMed ID: 30171804
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of linezolid and its major metabolites PNU-142300 and PNU-142586 in adult patients.
Sakurai N; Kawaguchi H; Abe J; Kuwabara G; Imoto W; Shibata W; Yamada K; Yasui H; Nakamura Y; Kakeya H
Pharmacotherapy; 2022 Sep; 42(9):707-715. PubMed ID: 35856168
[TBL] [Abstract][Full Text] [Related]
10. A standard dose of linezolid puts patients with hepatic impairment at risk of overexposure.
Liao R; Dong Y; Chen L; Wang T; Li H; Dong H
Eur J Clin Pharmacol; 2023 Jan; 79(1):149-157. PubMed ID: 36434292
[TBL] [Abstract][Full Text] [Related]
11. Linezolid-induced thrombocytopenia increases mortality risk in intensive care unit patients, a 10 year retrospective study.
Kim HS; Lee E; Cho YJ; Lee YJ; Rhie SJ
J Clin Pharm Ther; 2019 Feb; 44(1):84-90. PubMed ID: 30243033
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of a risk prediction model for linezolid-induced thrombocytopenia in elderly patients.
Qin Y; Chen Z; Gao S; Shen Y; Ye Y
Eur J Hosp Pharm; 2024 Feb; 31(2):94-100. PubMed ID: 35477677
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic drug monitoring and receiver operating characteristic curve prediction may reduce the development of linezolid-associated thrombocytopenia in critically ill patients.
Dong HY; Xie J; Chen LH; Wang TT; Zhao YR; Dong YL
Eur J Clin Microbiol Infect Dis; 2014 Jun; 33(6):1029-35. PubMed ID: 24515096
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for thrombocytopenia in patients receiving linezolid therapy: a systematic review and meta-analysis.
Zhang D; Xu Y; Wang X; Hou L; Xing M; Xu S; Guo R; Luo Y
Eur J Clin Pharmacol; 2023 Oct; 79(10):1303-1314. PubMed ID: 37578552
[TBL] [Abstract][Full Text] [Related]
15. High frequency of thrombocytopenia in patients with acute-on-chronic liver failure treated with linezolid.
Zhang YM; Yu W; Zhou N; Li JZ; Xu LC; Xie ZY; Lu YF; Li LJ
Hepatobiliary Pancreat Dis Int; 2015 Jun; 14(3):287-92. PubMed ID: 26063030
[TBL] [Abstract][Full Text] [Related]
16. A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia.
Hanai Y; Matsuo K; Ogawa M; Higashi A; Kimura I; Hirayama S; Kosugi T; Nishizawa K; Yoshio T
J Infect Chemother; 2016 Aug; 22(8):536-42. PubMed ID: 27321773
[TBL] [Abstract][Full Text] [Related]
17. Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy.
Niwa T; Suzuki A; Sakakibara S; Kasahara S; Yasuda M; Fukao A; Matsuura K; Goto C; Murakami N; Itoh Y
Clin Ther; 2009 Oct; 31(10):2126-33. PubMed ID: 19922883
[TBL] [Abstract][Full Text] [Related]
18. Retrospective analysis of the risk factors for linezolid-induced thrombocytopenia in adult Japanese patients.
Hirano R; Sakamoto Y; Tachibana N; Ohnishi M
Int J Clin Pharm; 2014 Aug; 36(4):795-9. PubMed ID: 24913359
[TBL] [Abstract][Full Text] [Related]
19. Impact of high plasma concentrations of linezolid in Taiwanese adult patients- therapeutic drug monitoring in improving adverse drug reactions.
Cheng CN; Wu CC; Kuo CH; Wang CC; Wang JT; Lin YT; Jhang RS; Lin SW
J Formos Med Assoc; 2021 Jan; 120(1 Pt 2):466-475. PubMed ID: 32600864
[TBL] [Abstract][Full Text] [Related]
20. Association of clinical factors with thrombocytopenia in patients receiving linezolid treatment: a retrospective study.
Thi Phuong Thao L; Duc Trung N; Thi My L; Minh Hong L; Viet Hoan B; Quang Hung V; Dang Hai P
J Infect Dev Ctries; 2024 Feb; 18(2):285-290. PubMed ID: 38484357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
